The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
- PMID: 17761736
- DOI: 10.1136/jcp.2007.050336
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
Abstract
Aim: To investigate the effect of polysomy 17 on HER-2 status as evaluated by immunohistochemistry (IHC), dual-colour fluorescence in situ hybridisation (FISH) and chromogenic in situ hybridisation (CISH).
Methods: Dual-probe FISH and single-probe CISH were performed to detect HER-2 gene amplification, and IHC to detect HER-2 expression, on 309 invasive breast cancers.
Results: Polysomy 17 was detected in 32.0% of the total number of breast cancers; it was detected in 12.3% of the IHC 0 or 1+ cases, 42.8% of the IHC 2+ cases and 66.0% of the IHC 3+ cases (p<0.001). In addition, there was a substantially higher rate of polysomy 17 in the IHC 2+ or 3+/FISH-negative cases than in the IHC 0 or 1+ cases (40.8% vs 12.3%; p<0.001). The FISH and CISH results were concordant in 299 cases (96.8%). Of the 10 discordant cases, FISH suggested amplification in five with disomy 17 and one with monosomy 17, whereas CISH pointed to borderline copy numbers in each of these six cases. The remaining four cases had high polysomy 17; CISH, but not FISH, indicated amplification.
Conclusions: Results suggest that an increase of HER-2 gene copy number secondary to polysomy 17 leads to HER-2 overexpression in some IHC 2+/3+ breast cancers, without gene amplification. The high level of concordance between FISH and CISH suggests that CISH is a valid alternative to FISH for assessing HER-2 gene amplification. However, cases in which CISH indicates the presence of borderline copy numbers or low levels of amplification may need FISH to rule out polysomy 17 and to determine HER-2 gene amplification status accurately.
Similar articles
-
Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol. 2002 Feb;15(2):137-45. doi: 10.1038/modpathol.3880505. Mod Pathol. 2002. PMID: 11850542
-
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
-
Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.Diagn Cytopathol. 2005 Dec;33(6):376-80. doi: 10.1002/dc.20401. Diagn Cytopathol. 2005. PMID: 16299744
-
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.Breast Cancer Res. 2005;7(2):R267-73. doi: 10.1186/bcr996. Epub 2005 Jan 26. Breast Cancer Res. 2005. PMID: 15743507 Free PMC article.
-
[HER2 gene amplification assay: is CISH an alternative to FISH?].Ann Pathol. 2003 Dec;23(6):617-22. Ann Pathol. 2003. PMID: 15094603 Review. French.
Cited by
-
Impact of Using Median vs. Mean in Calculating ERBB2 FISH Results in Breast Cancer.Cancer Med J. 2021 Dec;4(3):87-96. Epub 2021 Apr 15. Cancer Med J. 2021. PMID: 34095900 Free PMC article.
-
Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy.Eur J Breast Health. 2021 Mar 31;17(2):128-136. doi: 10.4274/ejbh.galenos.2021.2021-2-9. eCollection 2021 Apr. Eur J Breast Health. 2021. PMID: 33870112 Free PMC article.
-
Centromere 17 copy number gain reflects chromosomal instability in breast cancer.Sci Rep. 2019 Nov 29;9(1):17968. doi: 10.1038/s41598-019-54471-w. Sci Rep. 2019. PMID: 31784614 Free PMC article.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.Signal Transduct Target Ther. 2019 Sep 13;4:34. doi: 10.1038/s41392-019-0069-2. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 31637013 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous